x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Prova Education

Prova Education designs educational programs that address a broad spectrum of gaps in awareness, attitudes, skills, and competencies related to guideline-based care and evolving disease management options. Its mission is to serve as an innovative and relevant resource for clinical content that promotes change in practice and patient outcomes.

science & medicine medicine

All Episodes

00:00:00

Living with gMG: Navigating Personal, Professional,...

Prova Education ·

2025/04/02

Guest: Vera Bril, MD Guest: Nicholas J. Silvestri, MD While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans

en

00:00:00

Traditional MG Treatments: Balancing Benefits, Risks,...

Prova Education ·

2025/04/02

Guest: Vera Bril, MD Guest: Hans Katzberg, MD While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as

en

00:00:00

A Scientific Look at FcRn Antagonists: Mechanisms of...

Prova Education ·

2025/04/02

Guest: Vera Bril, MD Guest: Nicholas J. Silvestri, MD While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans

en

00:00:00

Precision Medicine for gMG: Tailoring Treatments...

Prova Education ·

2025/04/02

Guest: Vera Bril, MD Guest: Nicholas J. Silvestri, MD While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans

en

00:00:00

Treatment Advances in Generalized Myasthenia Gravis:...

Prova Education ·

2025/04/02

Host: Vera Bril, MD Guest: Jonathan Strober, MD The adult and pediatric diagnostic and treatment landscapes of generalized myasthenia gravis (gMG) are both similar and different. While current traditional therapies are often effective in the short term, selecting the most appropriate short- and longer-term treatment for each patient, whether adult or pediatric, brings with it unique individual challenges. These challenges include how best to utilize newer targeted agents in the

en

00:00:00

Preventing Myasthenic Crisis: Early Signs and...

Prova Education ·

2025/04/02

Guest: Vera Bril, MD Guest: Hans Katzberg, MD While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as

en

00:00:00

Ocular to Generalized MG: How and Why the Disease...

Prova Education ·

2025/04/02

Guest: Vera Bril, MD Guest: Hans Katzberg, MD While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as

en

00:00:00

Managing Side Effects in FcRn Therapy: Best Practices...

Prova Education ·

2025/04/02

Guest: Vera Bril, MD Guest: Nicholas J. Silvestri, MD While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans

en

00:00:00

Diagnostic Advances in gMG: Effective Tools and...

Prova Education ·

2025/04/02

Guest: Vera Bril, MD Guest: Hans Katzberg, MD While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as

en

00:00:00

New Frontiers in MG: How FcRn Antagonists Are...

Prova Education ·

2025/04/02

Guest: Vera Bril, MD Guest: Nicholas J. Silvestri, MD While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans

en

00:00:00

Autoantibodies Explained: Anti-AChR, Anti-MuSK, and...

Prova Education ·

2025/04/02

Guest: Vera Bril, MD Guest: Nicholas J. Silvestri, MD While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans

en

00:00:00

Second-Line Solutions in Metastatic TNBC: ADC...

Prova Education ·

2025/03/25

Host: Aditya Bardia, MD Host: Tiffany Traina, MD, FASCO When choosing an antibody-drug conjugate (ADC) for the second-line treatment of triple-negative breast cancer (TNBC), efficacy, sequencing, and management of toxicities are key. Do you know how best to choose a therapy for your patients? Our experts have the answers and strategies you need!

en

00:00:00

Making the Case for Dual Ang-2/VEGF-A Inhibition:...

Prova Education ·

2024/04/30

Host: Jennifer I. Lim, MD, FARVO Guest: Carl Regillo, MD What evidence do we have that blocking Ang-2 and VEGF-A is beneficial for patients? Tune in to hear Dr. Jennifer Lim and Dr. Carl Regillo examine the anatomical and biomarker evidence surrounding dual inhibition of Ang-2 and VEGF-A. Find out how bispecific targeting can benefit patients with neovascular age-related macular degeneration and diabetic macular edema.

en

00:00:00

Bowel Prep Hesitancy: What's It All About?

Prova Education ·

2024/03/20

Guest: Aasma Shaukat, MD, MPH Guest: David Johnson, MD In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing

en

00:00:00

Don't Flush Another Colonoscopy Down the Toilet

Prova Education ·

2024/03/20

Guest: Douglas Rex, MD Guest: Aasma Shaukat, MD, MPH In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing

en

00:00:00

Quality Indicators: How Do You Compare? Part 1

Prova Education ·

2024/03/20

Guest: Douglas Rex, MD Guest: Aasma Shaukat, MD, MPH In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing

en

00:00:00

Bowel Preparation Regimens: How Do They Compare?

Prova Education ·

2024/03/20

Guest: Aasma Shaukat, MD, MPH Guest: David Johnson, MD In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing

en

00:00:00

New and Emerging Agents

Prova Education ·

2024/03/20

Guest: David Johnson, MD In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect,

en

00:00:00

Quality Indicators: How Do You Compare? Part 2

Prova Education ·

2024/03/20

Guest: Douglas Rex, MD Guest: David Johnson, MD In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and

en

00:00:00

Screening Colonoscopy in 2024 and Beyond

Prova Education ·

2024/03/20

Guest: Douglas Rex, MD In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect,

en

134 results

Similar Podcasts

科学史评话最新专辑

科学史评话

Hablando con Científicos - Cienciaes.com

cienciaes.com

天方烨谈

基因频道

The Permaculture Podcast

Scott Mann

汪诘：科学有故事（主打）

科学有故事